Physician profile
John Patrick Farry
NPI 1174517635
$3,663.42
in general payments reported to CMS, 2019-2025
34 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $129 · 2021: $347 · 2022: $584 · 2023: $562 · 2024: $831 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $500.86 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $405.66 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $383.54 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $338.78 | 2021-2024 | Verquvo |
| Pfizer INC. | $306.76 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $247.54 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.26 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $122.05 | 2019-2025 | Farxiga |
| Alnylam Pharmaceuticals INC. | $111.35 | 2021-2025 | Onpattro |
| Esperion Therapeutics, INC. | $103.43 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $96.91 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $81.36 | 2019-2025 | Eliquis, Camzyos |
| Baxter Healthcare | $73.84 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Irhythm Technologies, INC. | $70.90 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Althera Pharmaceuticals LLC | $69.21 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $62.28 | 2024 | |
| Abbott Laboratories | $50.12 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $46.62 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $45.00 | 2019 | |
| Bridgebio Pharma, INC. | $34.32 | 2025 | Attruby |
| Kowa Pharmaceuticals America, INC. | $30.89 | 2019-2021 | |
| Boston Scientific Corporation | $28.97 | 2019 | |
| Lundbeck LLC | $28.23 | 2019-2020 | |
| Heartflow, INC. | $24.87 | 2023 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $21.90 | 2025 | |
| Lilly USA, LLC | $21.37 | 2025 | Zepbound, Mounjaro |
| Cleerly, INC. | $19.52 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.71 | 2020 | |
| Cvrx, INC. | $18.45 | 2024 | Barostim Neo System |
| Azurity Pharmaceuticals, INC. | $18.00 | 2024 | Edarbyclor |
| Lexicon Pharmaceuticals, INC. | $16.56 | 2024 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $14.42 | 2022 | |
| Medicure Pharma INC. | $13.74 | 2024 | Zypitamag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Farry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.